CCO Treatment Updates
Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents
Virtual Presentation
Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents
|
|
|
Joseph J. Eron, Jr., MD, discusses clinical data and strategies important for optimal use of next-generation NNRTIs on the management of HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize recent clinical data on the safety and efficacy of next-generation NNRTIs
- Describe the impact of NNRTI resistance mutations on response to both currently FDA-approved NNRTIs and next-generation NNRTIs
- Discuss the use of investigational or recently approved agents in combination with currently approved therapies to maximize outcomes in treatment-experienced HIV-infected patients
|
Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 1.21 MB
|
Case Vignettes
Clinical Management of a Patient Who Develops Additional Resistance Mutations When Maintained on a Failing Antiretroviral Regimen
|
|
|
Joseph J. Eron, Jr., MD, discusses the management of an HIV-infected male who experiences treatment failure and subsequently develops multiple resistance mutations
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss how emergent NNRTI mutations following virologic rebound may impact subsequent therapy decisions
- Describe the known predictors of etravirine virologic response
- Summarize data from clinical trials suggesting that achieving HIV-1 RNA < 50 copies/mL is possible in highly treatment–experienced patients
|
Selecting an Antiretroviral Regimen in a Treatment-Experienced Patient Who has Never Achieved Undetectable Viral Load
|
|
|
Pablo Tebas, MD, reviews considerations influencing management strategies in a patient with virologic failure and multidrug-resistant HIV.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the treatment goals of antiretroviral therapy for highly treatment–experienced patients
- Discuss how best to utilize HIV resistance testing to determine available antiretrovirals in highly treatment–experienced patients
- Explain strategies for the optimal use of antiretroviral agents in a new regimen for a treatment-experienced patient
|
Using Recently Approved Antiretrovirals in the Management of a Highly Treatment–Experienced HIV-Infected Woman
|
|
|
W. David Hardy, MD, discusses considerations when deciding whether to use raltegravir, maraviroc, and/or etravirine in the clinical management of a highly treatment–experienced HIV-infected woman.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the use of etravirine in combination with other new and existing antiretrovirals in triple class–experienced patients
- Summarize the clinical data on the efficacy of raltegravir among treatment-experienced individuals
- Define treatment options for HIV-infected patients with multidrug-resistant virus
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|